Clinical and histopathological research on predictive evaluation of the effect of radiotherapy combined with or without chemotherapy for lung cancer

肺癌放疗联合化疗疗效预测评价的临床及组织病理学研究

• 批准号: 15591300
• 负责人: HAYAKAWA Kazushige
• 金额: $ 2.3万
• 依托单位: Kitasato University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2003
• 资助国家: 日本
• 起止时间: 2003 至 2004
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-15591300/
• 关键词: Radiotherapy; Non-small cell lung cancer; telomerase activity; Tumor suppressor gene; Cancer gene; Prognostic factor; Radiosensitivity; Angiogenesis

In the present study, quantitative levels of telomerase activity and hTERT gene mRNA (hTERT) expression playing a key role in telomerase activation were analyzed in cancerous and non-cancerous lung tissues of 62 lung cancer patients by telomeric repeat amplification protocol and reverse transcription-PCR, respectively. The telomerase expression levels of each group of tissue samples were compared with clinicopathologic variables. Telomerase activity and hTERT were detected in cancerous tissues (75.8 and 75.8%, respectively), while these parameters were not observed in any non-cancerous tissues. In quantitative assessment of telomerase expression, both telomerase activity and hTERT were significantly correlated with lymph node metastasis (NO vs. N+, P<0.05). Telomerase activity also correlated with tumor cell differentiation and stage classification (P<0.05), but did not correlate with other clinicopathologic variables. The disease-free survival in patients with lung cancer demonstrated … More that patients with hTERT-positive tumor survived for a significantly shorter period than those with hTERT negative tumor (P=0.0334). Since hTERT levels are correlated with N factor which represents the true aggressiveness of patients' disease concerning the evaluation of clinical outcome, hTERT was found to be one of the important markers revealing biological malignant potentials for lung cancer. To reduce the normal tissue damag, we adopted three-dimensional (3D) conformal single high-dose boost radiosurgery (SRS) by using our spiro-analyzer respiratory gating system for peripheral T1 non-small cell lung cancer (NSCLC). Twenty-four palients were treated with a standard fractionation of 30 GY/10 fractions or 40 Gy/20 fractions and a single high-dose boost of 20 Gy using 3D non-coplanar SRS. Twenty tumors (83%) showed a local responce. No radiation pneumonitis greater than National Cancer Institute-Common Toxicity Criteria Grade 1 was noted except one patient had grade 2 pneumonitis. 3D conformal single high-dose boost SRS using our respiratory gating system was useful for the treatment of peripheral TI NSCLC. Less

本研究采用端粒重复序列扩增法和逆转录-聚合酶链反应（RT-PCR）技术，分别检测了62例肺癌患者癌组织和非癌组织中端粒酶活性和端粒酶活性调节基因hTERT mRNA的表达水平。将各组组织样本的端粒酶表达水平与临床病理变量进行比较。端粒酶活性和hTERT在癌组织中检测到（分别为75.8%和75.8%），而这些参数在任何非癌组织中均未观察到。端粒酶活性和hTERT表达与淋巴结转移显著相关（NO vs. N+，P<0.05）。端粒酶活性与肿瘤细胞分化程度和分期有关（P<0.05），但与其他临床病理因素无关。肺癌患者的无病生存率表明， ...更多信息 hTERT阳性肿瘤患者的生存期明显短于hTERT阴性肿瘤患者（P=0.0334）。由于hTERT水平与N因子相关，N因子代表了患者疾病的真实侵袭性，涉及临床结果的评估，因此发现hTERT是揭示肺癌生物学恶性潜能的重要标志物之一。为减少正常组织的损伤，我们采用了三维（3D）适形单次大剂量加强放射外科（SRS），使用我们的螺旋分析仪呼吸门控系统周围T1非小细胞肺癌（NSCLC）。24例患者采用3D非共面SRS进行30戈伊/10次或40戈伊/20次标准分割和20戈伊单次高剂量加强治疗。20个肿瘤（83%）显示局部反应。除1例患者发生2级肺炎外，未观察到大于国家癌症研究所常见毒性标准1级的放射性肺炎。使用我们的呼吸门控系统的3D适形单次高剂量加强SRS可用于治疗外周TI NSCLC。少

项目成果

Ten-year disease-free survival of a small cell lung cancer patient with brain metastasis treated with chemoradiotherapy.

一名脑转移小细胞肺癌患者接受放化疗后十年无病生存。

• 发表时间: 2004
• 期刊: Anticancer Res. 24・3b
• 作者: Niibe Y;Karasawa K;Hayakawa K
• 通讯作者: Hayakawa K

Radiation therapy in the treatment of lung cancer.

放射治疗治疗肺癌。

• 发表时间: 2003
• 期刊: JMAJ 46・12
• 作者: Kitamoto Y;Nakayama Y;Hayakawa K;et al.;Hayakawa K
• 通讯作者: Hayakawa K

Kitamoto Y, Nakayama Y, Hayakawa_K, et al.: "Retrospective study of treatment results for limite-stage small-cell lung cancer in National Nishigunma Hospital."J Jpn Soc Ther Radiol Oncol. 15・2. 145-150 (2003)

Kitamoto Y、Nakayama Y、Hayakawa_K 等：“国立西群马医院有限期小细胞肺癌治疗结果的回顾性研究”Jpn Soc Ther Radiol Oncol 15・2（2003）。

Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma : clinical outcomes in 245 subjects in a Japanese multiinstitutional study

立体定向大分割高剂量照射治疗 I 期非小细胞肺癌：日本多机构研究中 245 名受试者的临床结果

• 发表时间: 2004
• 期刊: Cancer 101・7
• 作者: Onishi H;Hayakawa K;et al.
• 通讯作者: et al.

Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma : clinical outcomes in 245 subjects in a Japanese multiinstitutional study.

立体定向大分割高剂量照射治疗 I 期非小细胞肺癌：日本多机构研究中 245 名受试者的临床结果。

• 发表时间: 2004
• 期刊: Cancer 101(7)
• 作者: Onishi H;Araki T;Shirato H;Nagata Y;Hiraoka M;Gomi K;Yamashita T;Niibe Y;Karasawa K;Hayakawa K;Takai Y;Kimura T;Hirokawa Y;Takeda A;Ouchi A;Hareyama M;Kokubo M;Hara R;Itami J;Yamada K.
• 通讯作者: Yamada K.